House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Cardiology

Elevated blood pressure and hypertension

ESC · 2024 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The ESC essential messages describe the classification and cardiovascular-risk approach in its guideline on elevated blood pressure and hypertension. These selected messages emphasize outcomes, treatment tolerability and individualized decisions; they are not a full prescribing algorithm.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Classification and risk

  • Blood-pressure-related cardiovascular risk is continuous rather than separated into two risk states by a hypertension threshold. [1]
  • The elevated-BP category includes office systolic BP of 120–139 mmHg or diastolic BP of 70–89 mmHg. Office BP of ≥140/90 mmHg remains the definition of hypertension. [1]
  • Assess absolute cardiovascular risk when evaluating or managing elevated BP. Hypertension-mediated organ damage indicates long-standing or severe hypertension and increased cardiovascular risk. [1]

Treatment goals

  • The guideline focuses on cardiovascular outcomes of BP-lowering interventions, rather than BP reduction as an outcome in isolation. [1]
  • For adults receiving BP-lowering treatment, the stated target is 120–129/70–79 mmHg only when well tolerated. Important exceptions apply, and individualized decisions remain the priority; the extract does not enumerate those exceptions. [1]

Limitations and use

  • Only the official key messages are summarized; the complete treatment thresholds, eligibility, drug choices and exceptions are not available in this extract.
  • The target must not be applied without tolerability assessment and the full guideline’s individualized exceptions.
  • A subsequent corrigendum is linked by the issuing society, but its recommendations are not represented in this source extract.
  • This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Elevated blood pressure and hypertension — focused recommendation source

    Selected recommendation material consulted

Clinical practice guideline

Publication details

Issuing organisation
ESC
First published
30 August 2024
Resource type
Clinical practice guideline · House clinical summary
Source setting
Europe

Earlier House summaries: hypertension in adults esc

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Classification and risk
  • Treatment goals
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House